Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S., a biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments in Turkey. It offers microbiology, genetic disorder, panel, sequencing, and food testing kits; and manual spin column and magnetic bead nucleic acid ext… Read more
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) - Net Assets
Latest net assets as of September 2025: TL1.68 Billion TRY
Based on the latest financial reports, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) has net assets worth TL1.68 Billion TRY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (TL2.15 Billion) and total liabilities (TL468.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | TL1.68 Billion |
| % of Total Assets | 78.19% |
| Annual Growth Rate | 133.61% |
| 5-Year Change | 361.7% |
| 10-Year Change | N/A |
| Growth Volatility | 663.55 |
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret - Net Assets Trend (2018–2024)
This chart illustrates how Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (2018–2024)
The table below shows the annual net assets of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | TL1.55 Billion | -11.44% |
| 2023-12-31 | TL1.75 Billion | +114.56% |
| 2022-12-31 | TL816.40 Million | -1.14% |
| 2021-12-31 | TL825.79 Million | +145.76% |
| 2020-12-31 | TL336.01 Million | +1839.79% |
| 2019-12-31 | TL17.32 Million | +81.67% |
| 2018-12-31 | TL9.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4895.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | TL1.89 Billion | 121.83% |
| Total Equity | TL1.55 Billion | 100.00% |
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret Competitors by Market Cap
The table below lists competitors of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hakers Enterprise Co Ltd
TWO:4432
|
$11.89 Million |
|
Sreeleathers Limited
NSE:SREEL
|
$11.90 Million |
|
Rimon Consulting & Management Services Ltd
TA:RMON
|
$11.90 Million |
|
Perpetual Energy Inc
PINK:PMGYF
|
$11.90 Million |
|
Kronologi Asia Bhd
KLSE:0176
|
$11.89 Million |
|
Conavi Medical Corp.
V:CNVI
|
$11.89 Million |
|
Purepoint Uranium Group Inc
OTCQB:PTUUF
|
$11.88 Million |
|
MAUNA KEA TECHNOL.EO -04
F:1MK
|
$11.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,751,677,031 to 1,551,365,517, a change of -200,311,514 (-11.4%).
- Net loss of 218,876,146 reduced equity.
- Other factors increased equity by 18,564,632.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | TL-218.88 Million | -14.11% |
| Other Changes | TL18.56 Million | +1.2% |
| Total Change | TL- | -11.44% |
Book Value vs Market Value Analysis
This analysis compares Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.46x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 130.01x to 1.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | TL0.08 | TL10.33 | x |
| 2019-12-31 | TL0.07 | TL10.33 | x |
| 2020-12-31 | TL2.82 | TL10.33 | x |
| 2021-12-31 | TL6.97 | TL10.33 | x |
| 2022-12-31 | TL7.42 | TL10.33 | x |
| 2023-12-31 | TL7.96 | TL10.33 | x |
| 2024-12-31 | TL7.05 | TL10.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -41.31%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.15x
- Recent ROE (-14.11%) is below the historical average (31.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 9.88% | 5.55% | 0.79x | 2.26x | TL-10.49K |
| 2019 | 43.16% | 33.55% | 0.61x | 2.11x | TL5.37 Million |
| 2020 | 94.67% | 69.60% | 1.07x | 1.28x | TL262.41 Million |
| 2021 | 56.52% | 105.66% | 0.48x | 1.12x | TL356.66 Million |
| 2022 | 40.47% | 122.90% | 0.31x | 1.05x | TL248.75 Million |
| 2023 | -11.26% | -57.37% | 0.18x | 1.12x | TL-372.49 Million |
| 2024 | -14.11% | -41.31% | 0.30x | 1.15x | TL-374.01 Million |
Industry Comparison
This section compares Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $92,065,864
- Average return on equity (ROE) among peers: 18.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) | TL1.68 Billion | 9.88% | 0.28x | $11.89 Million |
| Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) | $108.11 Million | 11.55% | 0.88x | $19.51 Million |
| Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) | $76.02 Million | 24.69% | 0.74x | $30.36 Million |